Fig. 5.

GSK-3β regulates PRMT4 protein stability. Empty vectors (A), GSK-3β expression (C), scramble (E), and shRNA (G) constructs were introduced into MLE12 cells, respectively. Cells were then treated with protein synthesis inhibitor CHX (20 μM) for different time intervals as indicated. PRMT4, GSK-3β, and β-actin immunoblotting was conducted. B, D, F, and H: the densitometry results of A, C, E, and G were plotted, respectively. Results are representative of 3 independent experiments. **P ≤ 0.01 vs. corresponding control.